The content on this site is intended for healthcare professionals only
Conferences
ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
ALL Assembly 2020
17 - 18 Jan 2020
Radisson Blu, Frankfurt, Germany
Patient quality of life in adult ALL
Zack Pemberton-Whiteley (UK)
23 Jan 2020
CAR-T cell therapy for ALL: Current challenges and future approaches
Dr Sara Ghorashian - University College London, London, UK
23 Jan 2020
Considerations for treatment sequencing in B-ALL
Prof Nicola Gökbuget - Universitätsklinikum Frankfurt, Frankfurt, Germany
23 Jan 2020
CART-T cell therapy in young patients with relapsed/refractory ALL
Prof Peter Bader - Universitätsklinikum Frankfurt, Frankfurt, Germany
23 Jan 2020
HSCT: Donor selection for patients with ALL
Prof Sebastian Giebel - The Maria Skłodowska-Curie Institute of Oncology, Gliwic...
23 Jan 2020
Therapy of Ph-positive adult ALL
Prof Oliver Ottmann - Cardiff University, Cardiff, UK
23 Jan 2020
The role of blinatumomab followed by HSCT in paediatric patients with ALL
Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy
23 Jan 2020
Defining the role of immunotherapy in B-cell ALL
Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy
23 Jan 2020
Long-term toxicities in paediatric ALL
Prof Kjeld Schmiegelow - University of Copenhagen, Copenhagen, Denmark
23 Jan 2020
How is minimal residual disease managed in patients with ALL?
Dr Renato Bassan - Ospedale dell'Angelo & Ospedale SS, Venice, Italy
23 Jan 2020
BLAST: Blinatumomab for minimal residual disease in patients with ALL
Dr Renato Bassan - Ospedale dell'Angelo & Ospedale SS, Venice, Italy
23 Jan 2020
Frontline therapy of ALL
Prof Hervé Dombret - University Paris Diderot, Paris, France
23 Jan 2020
BiTE therapy followed by HSCT vs CAR-T cells in young patients with R/R ALL
Prof Hervé Dombret - University Paris Diderot, Paris, France
23 Jan 2020
Treatment of Ph-negative ALL in adolescents and young adults
Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain
23 Jan 2020
The new era of ALL treatment
Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain
23 Jan 2020
Safety considerations for inotuzumab in patients with relapsed/refractory ALL
Prof David Marks - University Hospitals Bristol NHS Foundation Trust, Bristol, U...
23 Jan 2020
Novel therapeutic approaches in B-progenitor ALL
Dr Charles Mullighan - St. Jude's Children's Research Hospital, Memphis, USA
23 Jan 2020
Identifying cancer susceptibility genes in paediatric ALL
Dr Ching-Hon Pui - St Jude's Children's Research Hospital, Memphis, USA
23 Jan 2020
Defining high-risk acute lymphoblastic leukaemia
Dr Ching-Hon Pui - St Jude's Children's Research Hospital, Memphis, USA
23 Jan 2020
Latest concepts in frontline therapy for paediatric ALL
Dr Ching-Hon Pui - St Jude's Children's Research Hospital, Memphis, USA
23 Jan 2020
